We use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time. However, please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.


Success of EBUS service cuts patient waiting times

Central Manchester University Hospitals has become one of just a handful of hospitals in the UK to offer the EBUS diagnostic service.

Endobronchial ultrasound guided fine needle aspiration cytology (EBUS-FNAC) offers cancer and non-cancer respiratory patients, particularly those suspected of having tuberculosis, an optimal, prompt, high quality, minimally invasive and cost-effective diagnostic service.

CMFT began offering the service in October, along with Rapid On-Site Evaluation, or ROSE, and early results for the service have been very positive, with more than 97 per cent of procedures proving successful.

EBUS-FNAC was recommended by the National Institute for Health and Clinical Excellence (NICE) for diagnosis and staging of lung cancer through sampling of mediastinal lymph nodes, in 2011.

When combined with on-site adequacy assessment and provisional diagnosis by a specialist cytopathologist, EBUS-FNAC offers rapid diagnosis and the ability to triage material for microbiology, flow cytometry, diagnostic immunocytochemistry and molecular testing to facilitate personalised therapy.

CMFT is the only hospital trust in the Greater Manchester and Cheshire area to provide EBUS with consultant-driven ROSE and provisional diagnosis.

The introduction of the service has already cut patient waiting times and has been extended for use with non-cancer cases. Demand for the service continues to increase.

To find out more about the EBUS service contact our Respiratory or Cytology teams.